Difference between revisions of "Vortioxetine-fluvoxamine"

From Psychiatrienet
Jump to: navigation, search
Line 9: Line 9:
 
| info =  
 
| info =  
 
* {{theorSS}}
 
* {{theorSS}}
* fluvoxamine is a inhibitor of CYP2C9, which metabolizes vortioxetine.}}
+
* Fluvoxamine is a inhibitor of CYP2C9, which metabolizes vortioxetine.}}

Revision as of 13:50, 4 November 2015

Vortioxetine
Type Antidepressant
Group SMS
links
Medscape Vortioxetine
PubChem 9966051
PubMed Vortioxetine
Kompas (Dutch) Vortioxetine
Wikipedia Vortioxetine
Fluvoxamine
Type Antidepressant
Group SSRI
links
Medscape Fluvoxamine
PubChem 5324346
PubMed Fluvoxamine
Kompas (Dutch) Fluvoxamine
Wikipedia Fluvoxamine

Switch medication from vortioxetine to fluvoxamine.[1] [2]

Nietinrijdenbord.png Stop vortioxetine
  • Day 1: reduce dosage of vortioxetine to 5 mg/day.
  • Day 8: stop administration of vortioxetine.
Eenrichtingbord.png Start fluvoxamine
  • Day 8: start administration of fluvoxamine in a dosage of 50 mg/day.
  • Day 22: bloodlevel vortioxetine is now zero, so you can increase faster.
Infobord.png More information
  • Occurrence of the serotonin syndrome is not likely, but theoretically possible, so caution is necessary.
  • Fluvoxamine is a inhibitor of CYP2C9, which metabolizes vortioxetine.
  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.